Implantation Enhancement by Elective Cryopreservation of All Viable Embryos

Summary

A randomised controlled open-label clinical trial to compare the clinical pregnancy rates between fresh embryo transfer and elective all-embryo vitrification with thawing and transfer in a subsequent cycle in high-responders

Conditions

• Infertility
• OHSS

Interventions

PROCEDURE

Vitrification with subsequent-cycle embryo thawing/transfer

The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®). In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation.

PROCEDURE

Intensified luteal phase support for fresh embryo transfer

A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).

DRUG

Pregnyl®

1500 IU

DRUG

Utrogestan®

200 mg tid

DRUG

Progynova®

2 mg bid

DEVICE

CryoBioSystem®

CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws

Sponsors & Collaborators

• Universitair Ziekenhuis Brussel

  lead OTHER

Principal Investigators

• Samuel Santos-Ribeiro, MD · Universitair Ziekenhuis Brussel

• Christophe Blockeel, PhD · Universitair Ziekenhuis Brussel

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

40 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-05-31

Primary Completion

2017-02-28

Completion

2017-02-28

Countries

• Belgium

Study Locations